Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation
Autor: | J. Bolanos-Meade, Guido J Tricot, Athanasios Fassas, Michele Cottler-Fox, Aaron P. Rapoport, Carl Shanholtz |
---|---|
Rok vydání: | 2002 |
Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty medicine.medical_treatment Apoptosis Hematopoietic stem cell transplantation Transplantation Autologous Autologous stem-cell transplantation Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Multiple myeloma Aged Neovascularization Pathologic business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Transplantation Regimen Tamoxifen Methotrexate Immunology Female business Multiple Myeloma Progressive disease medicine.drug |
Zdroj: | Leukemialymphoma. 42(6) |
ISSN: | 1042-8194 |
Popis: | Tamoxifen has been shown to induce apoptosis in multiple myeloma cell lines and primary myeloma cells. Daily tamoxifen was given to 12 consecutive multiple myeloma patients who either relapsed following autologous stem cell transplantation (11) or had progressive disease on conventional chemotherapy (1). Methotrexate was also given biweekly to enhance the antiangiogenetic effect. Two patients achieved complete remission lasting 8 and 18 months. Two additional patients had stable disease (SD) for 7 and 11 months. All responders were men and the earliest signs of response were seen after approximately 6-8 weeks of treatment. The regimen was very well tolerated. Speculations about a possible mechanism of action of tamoxifen in multiple myeloma are discussed. |
Databáze: | OpenAIRE |
Externí odkaz: |